For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire (tezepelumab) for severe uncontrolled asthma
For more information read the patient information leaflet accessible here
For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire▼ (tezepelumab) for severe uncontrolled asthma
Click to jump to information about:
How to use Tezspire
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if there is anything you are not sure of.
For people aged 12 years and older the recommended dose for Tezspire is 210 mg (1 injection) every 28 days. It is given as an injection under the skin (subcutaneously).
Your doctor or nurse will decide if you can inject yourself or if your caregiver can do that for you. If so, you or your caregiver will receive training on the right way to prepare and inject Tezspire.
It's normal to feel nervous about giving yourself an injection. Once you learn how to take your new medication, you may find it’s much easier than you think. Keep in mind that you’ll only have to do it once every 28 days!
You can either inject with the pre-filled syringe or with the pre-filled pen (do not share these or use them more than once). You can watch a video guide on how to use them, or download the step-by-step guidance.
Full information and 'instructions for use' are also provided in your Tezspire carton, you should read this carefully each time you are injecting Tezspire as there may be new information.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Reporting side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.ukhttps://yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get as advised above.
GB-49707 | DOP: March 2024